120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer
Fernández Hidalgo O., González F., Gil A., Campbell W., Barrajón E., Lacave A.J.
Department of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain.
Magazine: American Journal of Clinical Oncology
Date: Sep 30, 1989Breast Cancer Area Medical Oncology
Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU).
Objective response was demonstrated in 19 patients (52.7%), stable disease in 7 patients (19.4%) and progression of the disease in 10 patients (27.7%). Similar response rate was observed according to tumor site (soft tissues, 50%; bone, 52%; lung, 63%; liver, 55%; and pleura and peritoneum, 42%) and previous treatment (previous chemotherapy, 48%; previously untreated, 61%).
Median duration of response was 8 months. Toxicity was characterized by stomatitis and myelodepression and required dose adjustments in 30% of patients. CDDP and 5-FU infusion deserve further investigation because it appeared to have substantial activity in this preliminary study in metastatic breast cancer.
CITATION Am J Clin Oncol. 1989 Oct;12(5):397-401
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.